Tailoring treatment strategies for NRF2-driven lung cancer [ 2018 - 2021 ]

Research Grant

Researchers: Dr Kate Sutherland (Principal investigator) ,  Dr Matthew Ritchie ,  Prof Benjamin Solomon

Brief description Lung cancer is the fifth most commonly diagnosed cancer and the most common cause of cancer-related death in Australia. Mutations in the KEAP1 gene are observed in a high number of lung cancer patients. These abnormalities are associated with poor prognosis, but may also present an opportunity to specifically target these cancer cells. We will utilise preclinical models to identify new personalised treatment strategies for patients that carry KEAP1 mutations.

Funding Amount $AUD 936,430.42

Funding Scheme Project Grants

Notes Standard Project Grant